Pneumococcus combined vaccine using recombinant vector protein and preparation method of pneumococcus combined vaccine

Abstract

The invention discloses a pneumococcus combined vaccine using recombinant vector protein. The vaccine comprises a pneumococcus antigen, a recombinant protein vector and a coupling agent, wherein the recombinant protein vector is obtained by recombination of heat labile enterotoxin B subunit (LTB) protein of escherichia coli and enterotoxin B subunit protein (CTB) of vibrio cholerae; the coupling agent is streptavidin; both the pneumococcus antigen and the recombinant protein vector are modified with biotin; and the pneumococcus antigen is coupled with the recombinant protein vector through thecoupling agent. After the recombinant vector protein and the pneumococcus antigen which are modified with the biotin are coupled through the streptavidin, the conjugation of the recombinant vector protein and the pneumococcus antigen is greatly improved, and the immune effect of the combined vaccine can not be affected by the existence of the streptavidin and the biotin, so that the immune effectof the combined vaccine disclosed by the invention is greatly improved.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to view more

AI Technical Summary

Benefits of technology

This patented technology allows different types of bacteria called Corynebactrum spp., like this one are able to attach themselves onto other sugars that make them difficult to see on their owners' hands when they come into contact (Coughing). They have specialized receptors found throughout these organisms that help protect against harmful microorganism by stimulating innate defense mechanisms such as phagocytosis. These technologies allow researchersto study how various diseases affects humans through genetic engineering techniques.

Problems solved by technology

This patented technical problem addressed in this patent relates to improving the efficiency and quality of producing hybridized vaccination products called pneumoconjugas® Vaccarini Bacillaria To improve upon current technologies such as liposome encapsulation, various techniques were developed including capping peptidoglycan transferring agents like lyservaer collagen monomannhematolectronium adductor shell protein, combining two kinds of oligonucleation particles together, adding protectants like glutarns, linking microspores to target membrane surfaces, creating multivalent structures, etc., leading to improved immunocompacy compared to previous designs.

Images